Osteoporosis drugs show promise in protecting spine by reducing tissue calcification

A potential new avenue for treating spinal issues may lie in existing osteoporosis medications, according to recent research. A study involving zebrafish suggests that bisphosphonate drugs, commonly used to treat bone density loss, could mitigate abnormal calcification in spinal tissues.

Researchers observed that as zebrafish aged, they developed spinal abnormalities, including abnormal calcification and vertebral fusion. These changes bear similarities to human intervertebral disc degeneration. The study indicates that this abnormal hardening isn't an initial occurrence but rather develops after supporting tissues are damaged, leading to mineral accumulation.

The research team further investigated the underlying mechanisms, finding that disruptions in fat metabolism, cell growth, and mineral regulation within the body play a role. This suggests that spinal degeneration might involve more than just wear and tear, with subsequent tissue damage triggering a cascade of changes that promote abnormal mineralization.

Testing bisphosphonate drugs on the zebrafish yielded significant results. The fish treated with these osteoporosis medications showed reduced mineral buildup in their spinal tissues and less vertebral fusion. The study also found that reducing food intake or using drugs that inhibit fat metabolism had similar effects. These findings point toward mineral regulation and fat metabolism as potential targets for future research into treating disc degeneration. However, the researchers emphasize that these results are preliminary, derived from animal models, and further studies are needed to confirm if these osteoporosis drugs can effectively treat human spinal degeneration.